NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes
Alessandro Laganà/altamedica.it
Aug 12, 2025, 03:37

Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes

Friends of Mediterranean Journal of Hematology and Infectious Diseases Group shared a post by on LinkedIn:

“Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE).

Nowadays, DOACs represent the gold standard for long-term anticoagulation, with low-intensity DOAC administration becoming increasingly used worldwide in such scenarios.

Although low-intensity apixaban and rivaroxaban are approved for clinical usage as secondary VTE prophylaxis, there is limited literature regarding their efficacy and safety with a long follow-up.
Here we report the long experience of Sapienza University in Rome.”

Read the full article here.

Article: Secondary Prophylaxis of  Venous Thromboembolism (VTE) with low dose Apixaban or Rivaroxaban: Results from a patient population with more than 2 years of median follow-up

Authors: Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini

Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes

Stay updated on the latest scientific advances in the field of thrombosis with Hemostasis Today.

Alessandra Serrao Alessandro Laganà Antonio Chistolini Apixaban Chiara Masucci Cristina Santoro DOACs Erminia Baldacci Giovanni Manfredi Assanto Giuseppe Leone Health Hematology Hemostasis Today LABORATORY Professionals International Livia Donzelli Mauro Passucci Medicine Rivaroxaban Sapienza University in Rome secondary VTE prophylaxis VTE
NewsFeed